Literature DB >> 9435180

Inhibition of neuronal Na+ channels by antidepressant drugs.

J J Pancrazio1, G L Kamatchi, A K Roscoe, C Lynch.   

Abstract

Although tricyclic antidepressant (TCA) blockade of cardiac Na+ channels is appreciated, actions on neuronal Na+ channels are less clear. Therefore, the effects of TCAs (amitriptyline, doxepin and desipramine) as well as trazdone and fluoxetine on voltage-gated Na+ current (INa) were examined in bovine adrenal chromaffin cells using the whole-cell patch-clamp method. Amitriptyline produced concentration-dependent depression of peak INa evoked from a holding potential of -80 mV with KD value of 20.2 microM and a Hill coefficient of 1.2. Although 20 microM amitriptyline induced no change in the rate or voltage dependence of INa activation, steady-state inactivation demonstrated a 15-mV hyperpolarizing shift. Similar results were observed for doxepin and desipramine. This shift in steady-state inactivation was associated with a slowed rate of recovery from the inactivated state. Contrasting results were observed with the atypical antidepressants: while 20 microM fluoxetine depressed peak INa by 61% and caused a 7-mV hyperpolarizing shift in steady-state inactivation, 100 microM trazodone decreased peak INa by only 19% and caused only a 3-mV shift. Although the magnitude of fluoxetine effects was similar to those of the TCAs, the onset of fluoxetine effects was substantially slower than for amitriptyline. In voltage-clamp and current-clamp measurements from neonatal rat dorsal root ganglion neurons, 20 microM amitriptyline decreased INa by 52% and depressed action potential dynamics consistent with enhanced Na+ channel inactivation. The effects of the TCAs on INa are similar to local anesthetic behavior and could contribute to certain analgesic actions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435180

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

Review 1.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

Authors:  Imju Jeong; Shin Hee Yoon; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-27       Impact factor: 3.000

Review 3.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

4.  Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Authors:  Marion Aubert; Rolf Osterwalder; Björn Wagner; Isabelle Parrilla; Icilio Cavero; Lucette Doessegger; Eric A Ertel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Block of persistent late Na+ currents by antidepressant sertraline and paroxetine.

Authors:  Ging Kuo Wang; Jane Mitchell; Sho-Ya Wang
Journal:  J Membr Biol       Date:  2008-04-17       Impact factor: 1.843

Review 7.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

Review 9.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  Inhibition of Kv4.3 potassium channels by trazodone.

Authors:  Yun Ju Chae; Jin-Sung Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.